Published: September 2015
Roots Analysis has announced the addition of “Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025” report to its portfolio. The study provides a comprehensive analysis of the current market landscape and future outlook of the growing pipeline of Immune Checkpoint Inhibitors (ICIs).
Rupali Verma, the principal analyst, said, “The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs for a broad range of cancer indications. Specifically, CTLA-4 inhibitors were pioneers in this segment. Yervoy was the only immunotherapeutic commercially available until other classes stepped in. The recent approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost. In addition, there are several novel checkpoint inhibitors (e.g. IDO, LAG-3, CD70, OX40, CD40, GITR, TIM-3, CD137/4-1BB, KIR, TDO, VISTA, CS1, NKG2A, GARP, ICOS) which are expected to gain traction in the future.”
Verma further stated, “The market is currently characterized by the presence of three marketed drugs and 34 drugs in clinical development.
Amongst other things, the report covers:
In addition to the initiatives taken by the bigger firms, the report covers many start-ups and small companies which have also emerged. Examples include
For additional details, please visit http://www.rootsanalysis.com/reports/view_document/immune-checkpoint-inhibitors-market-2nd-edition-2015-2025/101.html or email firstname.lastname@example.org
About Roots Analysis
Roots Analysis is a specialist market research company, sharing fresh and independent perspectives in the bio-pharmaceutical industry. The in-depth research, analysis and insights are driven by an experienced leadership team which has gained many years of significant experience in this sector. If you’d like us to help you with your growing business needs, get in touch at email@example.com
We are your partners with no equity
We fit in your budget
We love what we do
Chance to prove ourselves
Best in class quality of work
Most trusted consulting partner in the industry